<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368820</url>
  </required_header>
  <id_info>
    <org_study_id>01151</org_study_id>
    <nct_id>NCT03368820</nct_id>
  </id_info>
  <brief_title>Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry</brief_title>
  <official_title>Cardiovascular Morbidities and Lung Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which&#xD;
      excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer,&#xD;
      is associated with cardiovascular events that may impact on the therapeutic decision.&#xD;
&#xD;
      The aim of this registry is to determine if and how cardiovascular co-morbidities impact on&#xD;
      the physicians' decision for anticancer treatment in lung cancer patients by comparing it to&#xD;
      the European Lung Cancer Working Party (ELCWP) guidelines&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Treatment decision adequacy</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of physician's treatment decision to current ELCWP guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment decision adequacy according to histology</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of physician's treatment decision to current ELCWP guidelines separately in small (SCLC) and non-small lung cancer (NSCLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 3 cycles for chemotherapy (9 weeks) or 1 month after completion of radiochemotherapy (15 weeks)</time_frame>
    <description>Response rate in patients with cardiovascular co-morbidities and adapted treatment using (World Health Organisation (WHO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Survival will be measured from the day of diagnostic biopsy. All patients have to be followed until death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Neoplasm</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Treatment left at the discretion of the participant</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any untreated lung cancer whatever the treatment intent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of lung cancer, either NSCLC or SCLC patients and carcinoid&#xD;
             tumours&#xD;
&#xD;
          -  Untreated lung cancer of any stage and any treatment (including palliative care only).&#xD;
&#xD;
          -  Availability for participating in the detailed follow-up of the protocol.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Age above 18 years.&#xD;
&#xD;
          -  Presence of at least one co-morbidity:&#xD;
&#xD;
          -  Any active or past cardiac ischemia&#xD;
&#xD;
          -  Reduced left ventricular ejection fraction (&lt; 50%)&#xD;
&#xD;
          -  Obstructive cardiomyopathy&#xD;
&#xD;
          -  Valvular dysfunction (3 or 4/4; valvular replacement)&#xD;
&#xD;
          -  Arrhythmia (atrial flutter or fibrillation, significant ventricular arrhythmia,&#xD;
             2nd-3rd degree auriculo-ventricular block, Wolf-Parkinson-White and other similar&#xD;
             aberrant conduction, bifascicular block, arrhythmogenic right ventricular dysplasia)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure (BP) &gt; 160 millimeter of mercury&#xD;
             (mmHg) or diastolic BP &gt; 100 mmHg on ≥ 1 hypotensive drug) or controlled hypertension&#xD;
             on ≥ 2 concurrent hypotensive drugs&#xD;
&#xD;
          -  Active or treated peripheral arteritis (grade 2 or more)&#xD;
&#xD;
          -  Cerebrovascular events&#xD;
&#xD;
          -  Pulmonary embolism and/or thrombophlebitis or patients at high risk of thrombophilia&#xD;
             (homozygous Leiden factor…)&#xD;
&#xD;
          -  Aortic aneurism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thymoma and thymic malignancies, pleural mesothelioma.&#xD;
&#xD;
          -  Patient previously treated for lung cancer.&#xD;
&#xD;
          -  Tumours for which complete staging cannot be assessed.&#xD;
&#xD;
          -  History of prior malignant tumour, except non-melanoma skin cancer or in situ&#xD;
             carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year&#xD;
             disease free interval).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Berghmans, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ELCWP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Berghmans, MD, PhD</last_name>
    <phone>00322541311</phone>
    <phone_ext>3192</phone_ext>
    <email>thierry.berghmans@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Pascale Meert, MD, PhD</last_name>
    <phone>003225413111</phone>
    <phone_ext>3192</phone_ext>
    <email>nathalie.leclercq@bordet.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Berghmans, MD</last_name>
      <phone>0032/2/5390496</phone>
    </contact>
    <investigator>
      <last_name>Thierry Berghmans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Colinet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoit Colinet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid CsToth, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ingrid CsToth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Holbrechts, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane Holbrechts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Bonduelle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves Bonduelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebahat Ocak, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sebahat Ocak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung neoplasms</keyword>
  <keyword>cardiovascular co-morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

